Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR448851 in early Alzheimer's disease
2025-524581-14-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 8
01
Overview
Phase 2, randomised, double-blind trial of SAR448851 in Alzheimer's disease (AD) (3 arms), sponsored by Sanofi. Primary endpoints: Change from baseline to Week 48 in plasma p-tau217 and Number of participants experiencing at least one treatment-emergent adverse event. Planned start Sep 2026; status: authorised.
02
Drugs
SAR448851
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on 2025-524581-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-524581-14-00.